The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | IELSG32 trial: 88-month follow-up on MATRIX followed by auto-SCT in primary CNS lymphoma
Andrés Ferreri, MD, IRCCS San Raffaele Hospital, Milan, Italy, shares an update on the IELSG32 trial (NCT01011920), which is investigating the methotrexate plus cytarabine plus rituximab plus thiotepa (MATRIX) combination regimen followed by autologous stem cell transplantation (auto-SCT) in patients with primary central nervous system (CNS) lymphoma. Dr Ferreri gives an overview of the trial and discusses survival and neurotolerability data at a median follow-up of 88 months. Dr Ferreri reports that the MATRIX regimen was shown to be associated with a long-lasting survival benefit in patients with primary CNS lymphoma. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
